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In 1993 a number of cases of unexplained adult respiratory syndrome occurred in the southwestern United States. The
illness was characterized by a prodrome of fever, myalgia, and other symptoms followed by the rapid onset of a capillary leak
syndrome with hemoconcentration, thrombocytopenia, and pulmonary edema. Viral RNA sequences in the lungs identified a
new member of the hantavirus genus, Sin Nombre virus (SNV), unique to North America. Pulmonary endothelial cells were
heavily infected but were not necrotic. We speculated that this capillary leak syndrome was initiated by immune responses
to the SNV-infected pulmonary endothelial cells. We isolated a CD8/ cytotoxic T lymphocyte (CTL) clone directly from the
blood of a patient with the acute hantavirus pulmonary syndrome (HPS) which recognizes a SNV specific epitope on the
virus nucleocapsid protein (aa 234–242) that is restricted by HLA C7 and produces IFNg but not IL-4. We identified a
second CD8/ CTL epitope located within another site aa 131–139 on the nucleocapsid protein, which is HLA B35 restricted,
and a CD4/ CTL epitope located on a third site on nucleocapsid protein aa 372–380 using lymphocytes obtained during
HPS from another patient that were stimulated in vitro. Hantavirus specific CD8/ and CD4/ CTL may contribute to the
immunopathology and capillary leak syndrome observed in the HPS. q 1997 Academic Press
INTRODUCTION myalgia, headache, and malaise, which is indistinguish-
able from other common viral-like syndromes but all
In May of 1993 a number of cases of an unexplained cases of HPS have thrombocytopenia (Duchin et al.,
febrile adult respiratory distress syndrome occurred in 1994). This leads to a rapidly progressive pulmonary
the Four Corners area of the southwestern United States edema phase of HPS with hypotension and hypoxemia.
(CDC, 1993). The illness was characterized by fever, rap- Fluids aspirated from the trachea contain protein concen-
idly progressing pulmonary edema, marked increase in trations similar to that of serum, consistent with a capil-
hematocrit, and a decrease in platelets (Duchin et al., lary leak syndrome into the lung and many patients die
1994). Investigations demonstrated specific antibodies in during this phase (Duchin et al., 1994).
the sera of these patients using antigens of previously Capillary leaking in the lung is the hallmark of HPS.
identified different hantaviruses (Ksiazek et al., 1995). The virus antigen is mainly present in structurally intact
Hantavirus sequences were amplified from lung tissues endothelial cells (Zaki et al., 1995) and the dramatic clini-
of infected patients using PCR techniques with hantavi- cal manifestations are in the lung (Duchin et al., 1994).
rus conserved sequence primers. Nucleic acid analysis Individuals experiencing dengue hemorrhagic fever
subsequently indicated the agent Sin Nombre virus (SNV) (DHF) also have a capillary leak syndrome with hemo-
was a new member of the hantavirus group (Nichol et concentration and thrombocytopenia and they have ele-
al., 1993). vated levels of markers of T cell activation which are
The clinical illness designated hantavirus pulmonary significantly higher than in individuals experiencing un-
syndrome (HPS) has been divided into phases similar to complicated dengue fever or in control children (Kurane
infection caused by other members of the hantavirus et al., 1991).
group (Lukes, 1954; Powell, 1954; Koster and Jenison, These similarities in clinical and laboratory measure-
1997). Initially there is a febrile phase associated with ments in patients with the HPS and DHF syndromes lead
us to hypothesize that the HPS is caused by a massive
capillary leak syndrome in the lungs of infected individu-1 To whom correspondence and reprint requests should be ad-
als that is the result of marked T cell activation in thedressed at the Center for Infectious Disease and Vaccine Research,
infected target organ (Zaki et al., 1995), although thereUniversity of Massachusetts Medical Center, 55 Lake Avenue North,
Worcester, MA 01655. Fax: (508) 856-4890. are many differences between the two syndromes. HPS
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appears to be the result of a primary hantavirus infection mm03, LDH 2572, and lactate 4.0 mmol/liter. Pressors
were withdrawn at 2 weeks but dependence on ventila-in a nonimmune individual unlike DHF which may occur
in primary dengue infections (Scott et al., 1976), but epi- tion with high fractions of inspired oxygen persisted until
death 30 days after admission. Blood for immunologicaldemiologic evidence indicates that there is a significantly
increased risk for acquiring DHF during secondary den- studies was drawn within 4 h of admission. Circulating
immune complexes were not detected and levels of com-gue infections (Burke et al., 1988; Kouri et al., 1986; Hal-
stead, 1988). Despite this difference, the clinical and lab- plement were normal (F. Koster et al., unpublished data).
PBMC were separated on Hypaque–Ficoll (Boyum, 1968)oratory manifestations of these diseases suggest that
the underlying mechanisms of immunopathogenesis may and cryopreserved at 0707 at the University of New Mex-
ico and were shipped on dry ice for studies done at thebe similar.
A better understanding of the underlying mechanisms University of Massachusetts.
The second patient was a 44-year-old woman also inof HPS should help to improve treatment of patients and
to serve as a basis for developing potential approaches good health who had seen rodents in the barn and feed
bins of her domestic animals. She was admitted to afor prevention by immunization of individuals at high risk.
Little is known about cellular immune responses to HPS, local hospital with a 4-day history of malaise, myalgias,
nausea, and vomiting. She was hypotensive and tachy-but an increase in the number of activated circulating
CD8/ cells expressing HLA DR and CD25 antigens has pneic, had early pulmonary edema on chest X-ray, and
thrombocytopenia. She was transferred to the Universitybeen described in hemorrhagic fever renal syndrome
(HFRS) during illness along with an increase in the num- of New Mexico Hospital on the same day, where she
was unresponsive and cyanotic with an unobtainableber of activated T cells producing interferon gamma
(IFNg) (Huang et al., 1993). blood pressure. The WBC was 51,100 1 mm03, hemato-
crit 60.7%, platelets 48,000 1 mm03, LDH 1167, lactateWe decided to search for evidence of SNV-specific T
lymphocyte activation using peripheral blood cells ob- 9.3 mmol/liter, and albumin 1.5 mg/dl. Her cardiac index
fell rapidly from 2.4 to 1.3 liters/min/m2, blood pressuretained from patients with HPS. We selectively expanded
in vitro the T lymphocytes of a patient with the acute failed to improve despite pharmacologic pressor support,
and oxygenation remained poor despite maximal ventila-HPS. A CD8/ CTL clone was isolated from the peripheral
blood mononuclear cells (PBMC) obtained from this pa- tory support. Extracorporeal membrane oxygenation
(ECMO) was instituted. After 4 days of ECMO and ventila-tient who subsequently died from the illness. This HLA
C restricted CD8/ CTL clone recognizes a nine-amino- tor support and 6 days of intravenous pressors, she re-
covered uneventfully, except for the removal of largeacid (aa) epitope on the nucleocapsid protein (aa 234–
aa 242) of SNV and produces IFNg but not interleukin pleural effusions. Blood was drawn for immunologic
studies within 2 h of admission, and PBMC were sepa-4. We have also identified an HLA B-35 restricted CD8/
CTL epitope located between aa 131 and aa 139 and a rated, cryopreserved, and shipped to the University of
Massachusetts as described above.CD4/ CTL epitope between aa 372 and aa 380 on the
SNV nucleocapsid protein using lymphocytes obtained
during acute illness from a second patient with HPS. Establishment of T cell lines from acute blood
specimens
MATERIAL AND METHODS
We thawed the cryopreserved PBMC from the first pa-
Patients
tient and cultured the cells at a concentration of 1.5 1
106 per ml of RPMI 1640 medium (Life Technologies)These patients were recruited from among those re-
ferred to the University of New Mexico Hospital for the supplemented with 10% heat inactivated fetal bovine se-
rum (Life Technologies) and interleukin (IL)-2, 25 units/treatment of suspected hantavirus pulmonary syndrome.
The diagnosis of HPS was made using criteria that were ml (Collab. Biomedical products). After 2 weeks of culture
at 377 we added an anti-CD3 monoclonal antibody (12F6previously described (Duchin et al., 1994). The first pa-
tient was a 47-year-old woman in good health who had at 0.1 mg/ml) kindly supplied by Dr. Johnson Wong (Bos-
ton) and x-irradiated allogeneic feeder cells, as pre-swept rodent droppings in an unused house 1 week
before admission. She was admitted to a regional hospi- viously described (Walker et al., 1989; Littaua et al., 1991;
Takahashi et al., 1991). The phenotypes of the culturedtal with a 2-day history of fever, chills, headache, myal-
gias, and abdominal pain. At the onset of cough and the PBMC were determined after 6 weeks in culture by FACS
analysis as previously described (Littaua et al., 1991).radiologic appearance of pulmonary edema the next day
she was transferred to the University of New Mexico Cytokines produced by this T cell line were assayed
using commercial ELISA assays as previously describedHospital. Shock necessitating pressor therapy and respi-
ratory failure developed rapidly requiring mechanical (Littaua et al., 1991). Cytokine measurements were per-
formed 3 days after stimulation of T cell lines with theventilation and 100% inspired oxygen. The WBC count
was 27,500, hemoglobin 16.0, platelet count 47,000 1 anti-CD3 monoclonal antibody, at a final concentration
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of 0.1 mg/ml. The CD8/ enriched T cell line (NM 1) was expressed protein 652 amino acids in length (including
signal peptide), with an approximate molecular weightcloned by limiting dilution analysis. Cells grew in 22 of
the 120 wells seeded at 3 cells/well. Cells in three of 72 kDa (Spiropoulou et al., 1994). These cloned N and G1
ORF inserts were then subcloned into the pSE-1 vacciniathese 22 wells had cytotoxic activity similar to that of the
parental CD8/ T cell line. Most experiments used the virus vector under the spheroid in promoter, a poxvirus
late promoter which has been shown to induce signifi-parental T cell line NM 1 which grew better than the
subclones of T cells. Similar techniques were performed cantly higher levels of recombinant protein expression
than the frequently used P7.5 promoter (Pearson et al.,to identify SNV-N protein specific T cell lines with PBMC
from the acute blood specimen of a second donor (NM 1991). The correct orientation and the intact ORF of the N,
and G1 clones were confirmed by nucleotide sequence5) but we did not detect specific lysis of autologous B-
LCL infected with recombinant Vac/SNV-N virus by the analysis. The generation, selection, and screening of the
vaccinia recombinants were done using standard proce-bulk culture T cell lines of this patient. We then stimulated
another aliquot of thawed PBMC from this donor with dures (Earl and Moss, 1991; Earl et al., 1991). The stock
recombinants were grown in CV1 monolayers and theautologous B-LCL infected with Vac/SNV-N virus. We
then detected T cell lines with SNV-N-protein specific titers of the infectious progeny were determined by
plaque assay on CV1 cells. The expression of the N andactivity and the effector cells were analyzed after cloning
by limiting dilution as described below. G1 proteins by the vaccinia recombinants in CV1 cells
was assayed by immunoprecipitation with sera from HPS
Cytotoxic T cell (CTL) assays patients, and rabbit polyclonal antisera raised against
infectious SNV (kindly provided by T. Ksiazek). These
CTL assays were performed as previously described
antibodies are reactive with N and G1 proteins. In addi-
using EBV-transformed lymphoblastoid cell lines (B-LCL)
tion, an N-monospecific antibody was used to confirm
as target cells. 51Cr labeled B-LCLs were infected with
the identity of the N protein band.
a recombinant vaccinia virus expressing either the SNV
nucleocapsid (N) protein or the G1 glycoprotein. The gen-
Synthetic peptides
eration, screening, and selection of recombinant vaccinia
viruses by homologous recombination was performed as Peptides based on the published sequences of Sin
previously described (Earl and Moss, 1991; Earl et al., Nombre and related viruses were synthesized at the Pro-
1991) and is summarized below. Target cells were in- tein Chemistry Core Facility at the University of Massa-
fected overnight with the vaccinia recombinants at a mul- chusetts, directed by Robert Carraway, Ph.D., using an
tiplicity of infection of 15:1 or were pulsed with peptides automated Rainin Symphony peptide synthesizer. Pep-
at indicated concentrations for 30 min before effector tides were purified by HPLC. Amino acid analyses and
cells were added to 51Cr labeled target cells. CTL assays repeat synthesis of selected peptides were performed
were performed at indicated effector:target (E:T) cell ra- as indicated to confirm results.
tios. In one experiment mouse ascitic fluid which con-
tains an antibody (W6/32) that binds to a cross-reactive RESULTS
determinant on HLA class I molecules and blocks killing
Establishment of CD8/ T cell line directly in acuteby HLA class I restricted CD8/ CTL, was added to the
blood sample (NM 1)assay as previously described (Littaua et al., 1991).
We postulated that activated T cells in the PBMC ofVaccinia-hantavirus recombinant viruses
patients with HPS would express elevated levels of IL-2
receptors and some of these activated T cells wouldThe open reading frame (ORF) of the SNV nucleocap-
sid (N) protein gene (located on the virus S RNA segment) recognize epitopes on SNV-infected cells. We thawed
the cryopreserved PBMC and cultured the cells in vitrohas been cloned, expressed, and the recombinant N pro-
tein characterized earlier (Feldman et al., 1993). The virus in media containing 25 mg of IL-2/ml for 2 weeks. We
then stimulated the cultured cells with an anti-CD3 mono-M RNA segment region containing the potential G1 pro-
tein ORF was reverse transcribed from RNA extracted clonal antibody using an approach that Walker et al.
(1989) and we (Littaua et al., 1991; Takahashi et al., 1991)from the autopsy lung tissue of HPS case H10 (Spiropou-
lou et al., 1994). PCR amplifications utilized oligonucleo- have used successfully to isolate HIV-1 specific CD8/
cytotoxic T lymphocytes (CTL) from PBMC. After 6 weekstide primer G47(/), with sequence 5*AGCCGAGGATCC-
AGGAGATACAGAATGGTAGGGTGG 3* (added BamHI in culture, the cells were analyzed by fluorescent acti-
vated cell sorting and were predominantly CD8/ T cellssite indicated) and primer pG2007(0) with sequence
5*AACGGACTGCAGTTATGCACTGGCTGCCCATATG- (96.6%) with some CD4/ T cells (3.7%). Repeat analysis
of this NM#1 cell line several months later revealed itATC 3* (added PstI site and template for TAA stop codon
indicated). PCR products were cloned into the pGEM-3Z was 99.9% CD3/, 98.7% CD8/, and 2.6% CD4/. Superna-
tant fluids were analyzed for cytokine production 3 daysplasmid (Promega). This construct would generate an
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TABLE 1 ing the G1 glycoprotein. We prepared 15-aa peptides
overlapped by 9-aa residues of the SNV-N protein. ThePercentage Specific Lysis of Target Cellsa Expressing SNV-N
nucleocapsid protein is large (428 aa); therefore, we ini-Protein by CD8/ T Cells after Limiting Dilution
tially screened 23 15-aa peptides selected because they
Effectors from well# Vac/N Vac/G1 contained a motif for binding to HLA A2 (Engelhard, 1994)
and the patient’s HLA alleles were A2, 28, B39, w6, C7.
3-2 29.9 03.7
The results in Table 2A demonstrate that specific lysis3-3 55.6 04.8
was observed on target cells pulsed with peptide 39 but3-4 34.8 04.4
51Cr Min/Max release 17.9 18.1 was not observed on target cells pulsed with the other
22 peptides selected based on nucleocapsid protein se-
a Autologous B-LCL were infected with recombinant vaccinia viruses quence and HLA A2 motifs (Table 2A and data not
containing a gene encoding the SNV-N or SNV-G1 proteins. Twenty-
shown). Experiments were then performed using differ-two wells grew out of 120 wells that were seeded with three cells/
ent concentrations of peptide 39 to pulse target cells forwell. Cells from the other 19 wells that grew had no cytotoxic activity
when they were screened for percentage specific lysis. recognition by TCR on NM 1 CD8/ CTL. The results
shown in Table 2B demonstrate specific lysis of target
cells pulsed with peptide at concentrations of 2.5 and
after stimulation with anti-CD3 and the cells produced a 25 mg/ml.
high level of IFNg (1382 pg/ml) but not IL-4 (2 pg/ml)
compared to 76 pg/ml of IFNg and 2 pg/ml IL-4 produced
Recognition of variant hantavirus N proteinby the control feeder cells.
sequences by the NM 1 CD8/ CTL line
Localization of CD8/ CTL epitope on the Sin Nombre
We tested target cells pulsed with peptides synthe-
virus nucleoprotein
sized based on published sequences of several other
hantaviruses (Stohwasser et al., 1990; Schmaljohn et al.,We subcloned this CD8/ T cell line (NM 1) at 3, 10,
and 30 cells/well. The majority of wells which received 1986, 1995; Henderson et al., 1995; Nerukar et al., 1994;
Parrington and Kang, 1990; Chizhikov et al., 1995; Hjelle10 or 30 cells/well were positive for growth, but only 22
of 120 wells had growth after seeding at 3 cells/well. et al., 1994, 1995) to determine the specificity and cross-
reactivity of this CTL epitope. The results are shown inTable 1 shows results of screening the cells from the
growing wells seeded at 3 cells/well for CTL activity on Table 3. Several SNV strains are completely conserved
in the sequence of the nucleocapsid protein representedautologous B-LCL that were infected with either vaccinia-
SNV N or G1 recombinant viruses. Similar screening of by peptide 39, which was recognized by this clone. A
peptide was made with a single E to D change at aa 238cell lines derived from two other patients was negative
for CTL lysis of autologous B-LCL infected with these based on a mutation reported on other SNV sequences
(Henderson et al., 1995; Nerukar et al., 1994). Thisrecombinants. We present below the results using an
alternate strategy. change resulted in a significant decrease in the level of
lysis by NM 1. Peptides with two substitutions, i.e., E rWe produced synthetic peptides based on the se-
quence of the N protein of SNV (Feldman et al., 1993) D at aa 234, and A r E at aa 242 based on the sequence
of SNV-like viruses from New York (Hjelle et al., 1995)because we observed significant killing of autologous
cells expressing nucleocapsid protein by T cells seeded were not recognized by the NM 1 CD8/ T cells. As would
be expected from these results, peptides based on thewith as few as three cells and no killing of cells express-
TABLE 2
Localization of CD8/ CTL Epitope on SNV N Protein
Experiment A: Specific lysis by CD8/ T cell line of target cells pulsed with SNV-NCP Peptidesa
Effector 30 33 39 40 45 47 55 62 63 64 None
NM 1 06.9 07.4 67.9 00.2 00.8 00.1 06.3 04.6 06.8 01.6 02.9
Min/Max 24.6 27.8 25.7 22.2 22.7 22.6 25.8 27.3 27.7 25.7 24.4
Experiment B: Peptide 39 dose–response lysis of target cells
E:T 25 mg/ml 2.5 mg/ml 0.25 mg/ml None
Effector 50 63.7 43.7 00.62 04.1
NM1 25 64.1 39.2 0.6 05.3
51Cr Min/Max 22.5 20.5 19.9 25.2
a Autologous B-LCL were pulsed with 15 aa long synthetic peptides of N protein at a final concentration of 25 mg/ml. The E:T ratio was 50:1.
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sequences of more distant hantaviruses, e.g., Prospect
Hill (Parrington and Kang, 1990), Puumala (Stohwasser
et al., 1990) and Hantaan 76-118 (Schmaljohn et al., 1986)
were not recognized. Therefore this CD8/ CTL epitope
is not conserved on the N proteins of other known mem-
bers of the hantavirus genus.
Definition of CD8/ CTL epitope on SNV N protein
We wanted to define more precisely the epitope on
SNV-N protein located within aa 229–aa 243 that was
contained in peptide 39. A series of synthetic peptides
was generated with N and C terminal truncations. The
results are shown in Table 4. The smallest peptide recog-
nized (SNV N 39H) is a nine-aa peptide from aa 234 to
aa 242. A deletion of either aa 234 or aa 242 resulted in
a loss of recognition. It is interesting that this defined
peptide does not contain a reported motif for HLA binding
peptides. The HLA A2 binding motif contained within
peptide 39, the original larger peptide, was between aa
233 and aa 240 with methionine at position 2 and leucine
at position 9 of the sequence. The epitope that is recog-
nized by this SNV specific CD8/ CTL clone begins at aa
234 and extends to aa 242, and peptides that do not
include the alanine at position 242 are not recognized.
HLA restriction of lysis by SNV-N specific CD8/ CTL
Preliminary experiments using autologous target cells
infected with the recombinant vac/SNV N virus demon-
strated significant lysis (36%) by the NM 1 CD8/ T cell
line that was reduced to 1% by addition of the anti-HLA
class I antibody W 6/36 (data not shown). This confirmed
the HLA class I restricted nature of killing by this CD8/
T cell line.
The nonamer peptide that contains the epitope has a
sequence that has not been reported to be a motif for
HLA class I alleles. We used multiple allogeneic target
cells that were partially matched with this donor’s HLA
alleles or peptide pulsed target cells. None of 13 HLA-
A-2 matched allogeneic target cells were lysed and 0 of
3 HLA-A-28 matched target cells were lysed; however, 6
of 9 HLA-C7 matched targets were lysed and only 1 of
8 B39 matched targets, which also shared HLA-C7, was
lysed. Therefore, the restricting HLA allele appears to be
C7 (data not presented). Table 5 contains results of a
dose–response curve with peptide 39 on 5 allogeneic
target cells matched at HLA C7 and an HLA-mismatched
control. These results indicate that target cells matched
at HLA C7 are lysed in a dose dependent fashion and
mismatched targets are not lysed. The level of lysis of
HLA-C7 matched allogeneic target cells varies, and this
may be due to reported C7 variants.
Establishment of CD8/ and CD4/ SNV-specific T cell
clones following stimulation in vitro
We initiated studies with the PBMC of another donor
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(NM 5). Cryopreserved PBMC obtained during the acute
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TABLE 4
Definition of CD8/ CTL Epitope on SNV-NP
aa aa aa aa aa aa aa aa aa aa aa aa aa aa aa
PeptideII 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 Lysisa
SNV N39 V K D W M E R I D D F L A A R ////
SNV N39A W M E R I D D F L 0
SNV N39B D W M E R I D D F L 0
SNV N39C K D W M E R I D D F L 0
SNV N39D W M E R I D D F L A 0
SNV N39E W M E R I D D F L A A ////
SNV N39F D W M E R I D D F L A 0
SNV N39G M E R I D D F L A A ////
SNV N39H E R I D D F L A A ////
SNV N39I R I D D F L A A 0
SNV N40 R I D D F L A A R 0
a ////, Level of lysis is similar to that observed on peptide 39 (25 mg/ml) pulsed target cells as stated in Table 2; 0, no convincing lysis was
observed
terestingly the cells from well 10-2 (the CD4/ T cell en-illness were thawed and cultured with IL-2 as described
riched cell line) grew in 19 of 60 wells seeded, but only aabove but bulk cultured cell lines did not show specific
very low level (9%) of specific lysis of Vac/SNV-N-infectedlysis of autologous B/LCL infected with the recombinant
targets was observed using these cells as effectors (dataVac/SNV-N virus. Attempts were then made to identify
not shown). We thought that this may have been due toSNV-N specific CTL following stimulation in vitro with
the fact that this cell line was predominantly CD4/, sorecombinant Vac/SNV-N virus-infected autologous B-
we tested the ability of the subcloned 10-2.16 (CD4/) TLCL in a bulk culture CTL assay done 7 days later. The
cell line to lyse autologous B-LCL infected with live Vac/level of lysis of autologous B-LCL exposed to Vac/SNV-
SNV N-protein or pulsed with a boiled antigen prepara-N virus was somewhat higher than the level of lysis of
tion of Vac/SNV-N infected cells. The results in Table 6control B-LCL (data not shown) so the cultured cells
demonstrate that the 10-2 subcloned CD4/ T cells (clonewere restimulated with anti-CD3 and were cloned by
10-2.16) lyse the Vac/SNV-N-antigen pulsed autologouslimited dilution. Of 120 wells seeded with 10 cells/well,
target cells to a much greater degree than targets in-64 wells had growing cells and cells in three wells lysed
fected with live recombinant Vac/SNV-N virus. On theVac/SNV-N virus infected targets to a significant degree.
other hand the CD8/ CTL line 10-3 lysed infected butFluorescent analysis of cells in wells with lytic activity
not antigen pulsed target cells.revealed that the cells in well 10-2 contained predomi-
Epitopes recognized by these CD8/ and CD4/ T cellnantly CD4/ T cells (89% vs 18% CD8/) and cells in well
clones were localized using the 15-mer peptides that10-3 were 99.9% CD8/ and 0.012% CD4/. Following a
overlap by 9 aa which were used to define the HLA C7-limiting-dilution subcloning, cells grew in 22 of the 60
restricted CD8/ CTL epitope described above. Peptidewells seeded at 10 cells/well with the CD8/ T cell line
pulsed autologous B-LCL were tested for recognition by(10-3) and cells from all 22 of these wells killed Vac/
SNV-N-protein infected cells to a significant degree. In- these CTL clones. A total of 70 overlapping peptides
TABLE 5
Dose–Response Study of Lysisa by UNM 1 CD8/ CTL of Peptide 39 Pulsed HLA C7 Matched Target Cells
Specific immune lysis of autologous and HLA partially matchedb target cells
Peptide Autologous GM07254 KB4 PG 66390 JK
(mg/ml) A2,28,B39,w6,C7 A1,B39,C7 A1,2,B7,8,C7 A2,3B7,27,C7 A3,24,B7,62,C7 A3,24,B35,C4
25 44.2 54.6 31.5 19.1 13.4 7.2
2.5 42.1 58.7 27.1 10.3 11.1 4.2
0.25 25.1 43.6 7.2 0.6 02.2 0.3
0.025 5.3 9.3 0.8 02.7 1.2 3.5
— 03.3 01.0 00.2 02.5 01.6 1.6
a E:T ratio of 10:1.
b HLA alleles that match are underlined.
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TABLE 6 based on hantavirus published sequences. The results
shown in Table 8 indicate that this CD4/ CTL clone doesPercentage Specific Lysis by the CD8 CTL Line and the Subcloned
not lyse the Hantaan virus peptide-pulsed target cells,CD4/ CTL Clone T Cell of Infected or Antigen Pulsed Target Cellsa
Expressing SNV-N Protein but does lyse target cells pulsed with peptides represent-
ing more closely related virus strains, e.g., El Moro Can-
NM 5 E:T yon with a K-R change at aa 378 and Puumala with the
same K r R change at aa 378 and an I-L change at aaVac-SNV-N
378. The Hantaan virus peptide that is not recognizeda. (live) Vac (live)
has an aspartic acid to glycine (D-G) mutation at aa 376
Well 10-2 10 9.5 03.6 and an I-V change at aa 381.
Well 10-3 10 45.7 03.3 Several truncated peptides were also synthesized with
a deletion of aa 367 –aa 371 which were conserved.
Vac-SNV-N Vac-SNV-N
Peptide 62g based on aa 372 –aa 380 was recognizedb. (live virus) (boiled antigen)
very well, and a substitution at aa 381 from I to V (Han-
Well 10-2.16 15 15.6 55.8 taan virus) did not effect recognition (peptide 62d). The
Well 10-3 15 79.0 00.2 change from D to G at position 376 resulted in no recog-
nition of the Hantaan virus sequence by the SNV-specifica 103 Target cells were incubated with effector cells for 5 h.
CTL clone.
The CD8/ CTL line 10-3 recognized peptide 22 aa
127–aa 141, but did not recognize the overlapping N
covering the SNV-N protein from aa 1 and aa 428 were terminal peptide 21 (aa 121–aa 135) or C-terminal pep-
used to pulse autologous B-LCL target cells. Only 5 of tide 24 (aa 133 –aa 147) (data not shown). Peptides were
the 70 peptides sensitized target cells for lysis above synthesized for closely related strains of SNV isolated
10% specific lysis in a screening assay at a peptide con- in the same southwestern region or in New York. Table
centration of 25 mg/ml. These 5 peptides were then re- 9 shows the lysis of target cells pulsed with these pep-
tested in a dose–response assay. The results shown in tides. The NY strain derived peptide sensitized target
Table 7 indicate that the CD8/ CTL line 10-3 kills target cells to a similar degree as the SNV peptide which is
cells pulsed with peptide 22 (aa 127–aa 141) and that consistent with its identical sequence except for a L r
the CD4/ T cell clone 10-2.16 lyses target cells pulsed I conserved mutation at aa 131. Target cells pulsed with
with peptide 62 (aa 367–aa 381). a peptide based on the El Moro Canyon virus with an
The CD4/ CTL clone lysed autologous target cells A r T change at aa 130 and an I r V change at aa 133
pulsed with SNV-N peptide 62 (aa 367–aa 381 RTQSMG- were also lyzed but to a lesser degree. Peptide based
IQLDQKIII) a sequence which is highly conserved on the on the Puumala sequence with changes A r T at aa 130
prototype Hantaan virus sequence from aa 367 to aa 375 and L r I at aa 131 also sensitized the target cells
but differs at aa 376, aa 378, and aa 381 (RTQSMGIQL- for lysis, and the nonomer peptide 22D based on SNV
sequence aa 131–139 also were lysed.GQRIIV) as shown in Table 8. Peptides were synthesized
TABLE 7
Specific Lysis of SNV N Peptide Pulsed Target Cellsa by CD8/ T Cell Line 10.3 and CD4/ CTL Clone 10-2.16
Clone
NM 5 E:T
Peptide 2 (aa 7–aa 21) Peptide 22 (aa 127–aa 141)
25 2.5 0.25 25 2.5 0.25 —
10-3 10 8.8 00.1 03.4 89.9 62.8 40.3 3.3
Min/max 14.3 14.0 14 16 13 13 12.6
Peptide 34 (aa (199–aa 213) Peptide 47 (aa 277–aa 291) Peptide 62 (aa 368–aa 381)
25 2.5 0.25 25 2.5 0.25 25 2.5 0.25
10-2.16 10 16 01.8 2.8 13.6 11.5 5.4 49.2 57.4 37.5
Min/max 12.9 12.7 13.1 13 13 13.3 22.5 15.1 13.5
a Target cells were incubated with effector cells for 5 h.
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TABLE 8
Percentage Specific Lysis by CD4/ CTL Clone 10-2.16 of Target Cellsa Pulsed with Peptides Based on SNV Peptide-62 Related Hantavirus
Sequences and Truncation of Four N-terminal aa (371–381)
Peptide conc.
(mg/ml)
aa aa aa aa aa aa aa aa aa aa aa aa aa aa aa
Virus 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 25 mg 2.5 mg
Sin Nombre
(Spiroupoulou
et al., 1994)
NM H10 R T Q S M G I Q L D Q K I I I 49.3 53.7
El Moro (Hielle
et al., 1994)
Canyon R T Q S M G I Q L D Q R I I I 70.6 40.5
Puumala
GC1820
(Stolwasser
et al., 1990) R T Q S M G I Q L D Q R I I L 53.0 32.8
Hantaan 76-118
(Schmaljohn
et al., 1986) R T Q S M G I Q L G Q R I I V 01.7 04.5
62c M G I Q L D Q K I I I 56.9 48.7
62d M G I Q L D Q K I I V 83.6 54.5
62a M G I Q L G Q K I I I 3.6 01.6
62g G I Q L D Q K I I 83.8 73.5
a 103 Target cells were pulsed with peptide at indicated concentration and incubated with effector cells for 5 h.
We then performed experiments to attempt to define fine the HLA restriction allele using multiple HLA partially
matched allogenic B-LCL as target cells infected withthe HLA restricting alleles for these CD8/ and CD4/ CTL
lines. The donor of the CD8/ CTL line (10-3) has the Vac/SNV-N virus or pulsed with peptides are summarized
in Table 10. The only allogeneic target cells that werefollowing HLA alleles A24, B35, 44, Cw 4,5. The results
of a series of experiments which were performed to de- lysed convincingly by this CD8/ clone shared HLA B35
TABLE 9
Percentage Specific Lysis by the CD8/ CTL Line 10-3 of Target Cellsa Pulsed with Peptides Based on the Sequence
of Closely Related Viruses (El Moro Canyon, NY)
Peptide conc.
(mg/ml)
aa aa aa aa aa aa aa aa aa aa aa aa aa aa aa aa
Virus 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 25 2.5 mg 0.25 mg
Sin Nombre
NMH10
(Spiroupoulou
et al., 1994) L S F A L P I I L K A L Y M L ND 45 21.2
El Moro Canyon
(Hjelle et al.,
1994) T V 43.2 21 3.7
New York
(Hjelle et al.,
1995) I 75.6 69.4 52.3
Puumala
GC1820
(Stohwasser
et al., 1990) I G T I 80.8 23.6 74.6
Peptide 22C A L P I I L K A L 92.2 28.6 01.4
Peptide 22D L P I I L K A L Y 77.5 73.9 67.8
a 103 Target cells were pulsed with peptide at indicated concentration and incubated with effector cells for 5 h.
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TABLE 10
Percentage Specific Lysisa by UNM CD8/ CTL Line 10-3 of Target Cellsb Sharing HLA-B35
Peptide Autologous NM 3 HMy.C1R JK
(mg/ml) A24 B35, 44Cw4,5 A2,B35, Cw7 B35.01 A2,24,B7,62,C3,7
2.5 68.0 85.3 73.7 1.4
0.25 60.7 80.2 69.2 1.8
— 06.2 06.6 06.5 01.4
Min/max
2.5 13.6 15.6 32.6 16.2
0.25 15.4 18.9 37.1 16.6
— 12.6 23.5 24.5 15.8
a E:T ratio of 15:1 was used.
b 103 Target cells were pulsed with peptide at indicated concentration and were incubated with effector cells for 5 h.
(Table 10 and data not shown). Furthermore a cell line cells, and a monocytic infiltrate (Zaki et al., 1995). Periph-
eral blood smears and pleural effusions contains largewhich only expressed HLA B35 (Hmy C1R B35.01) was
immunoblast-like T cells that are predominantly CD8/ bylysed to confirm that HLA B35.01 is the restriction allele
flow cytometry (F. Koster et al., unpublished data). Wefor this CD8/ CTL line. These results were confirmed in
speculate that during HPS these circulating large acti-other experiments (data not shown).
vated cells would include SNV specific CD8/ and CD4/The results of experiments performed in an attempt to
T cells. We used media containing low concentrationsdefine the restricting allele for the CD4/ CTL clone 10-
of IL-2 to selectively grow in vivo activated T cells from2.16 are shown in Table 11. There are some class II
one patient’s PBMC, without any antigenic or mitogenicalleles that were not reported for some target cells, but
stimulation during the initial culture period. In the secondthe allogeneic target cells which were lysed convincingly
patient we stimulated SNV N protein specific CD8/ andshared DQw2 or DR3 (VA09 and PG) and those which
CD4/ CTL clones from an acute blood specimen. Theseshared other class II alleles were not. Therefore, the data
results suggest that the T cells infiltrating the lungs dur-suggest that either DQw2 or DR17(3) is the restricting
ing HPS may include SNV-specific CD8/ and CD4/ Tallele for this CD4/ CTL clone (Table 11 and data not
cells, but further studies are needed to address thisshown).
question.
What do the SNV-specific CD8/ and CD4/ CTL doDISCUSSION
during HPS? We provide no direct data on the roles these
We present evidence that SNV specific CD8/ and SNV-specific CD8/ and CD4/ CTL, detected in the blood
CD4/ CTL were circulating in two patients with fulminant of patients with HPS, may play in the pulmonary pathol-
HPS. This is the first evidence of SNV-specific CD8/ and ogy of HPS. We speculate that they recognize SNV-in-
CD4/ CTL responses during HPS. The lungs of patients fected alveolar endothelial cells (Zaki et al., 1995) in the
lungs and may trigger immunopathology by releasingwith HPS contain inflammatory cells, predominantly T
TABLE 11
Percentage Specific Lysisa of Allogeneic Partially HLA-Matched Target Cellsb Pulsed by the CD4/ CTL Clone 10-2.16
with Peptide 62 (aa 367–aa 381)
Autologous VA-09 PG K0032
Peptide DP DQw DR DRW DP DQw DR DRw DP DQw DR DQw DR DRw
(mg/ml) 2, 5(1)c 17(3)c14(6)c 52 1,2 2, 3 52 2 3 9(3)5(1) 9,12(5) 52
0.5 57.1 70.1 51.1 6.6
0.05 25.1 25.9 27.4 01.3
— 0.4 03.4 0.1 2.6
Min/max
0.5 13.7 19.7 9.1 16.7
0.05 14.7 19.3 92 15.1
— 12.6 18.2 8.7 13.9
a An E:T ratio of 15:1 was used.
b 103 Target cells were pulsed with peptide and incubated with effector cells for 5 h.
c Allele noted in ( ) is former assignment, replaced by results by high resolution nomenclature.
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lymphokines. These CD8/ and CD4/ T cells produce quently Johnson et al. described an HLA C restricted
allele on HIV-1 gp160 (Williams et al., 1992). HLA C7 ishigh concentrations of IFNg. Although little IL-2 was de-
tected after stimulation of this clone, IL-2 probably be- a common HLA allele in North America including Native
Americans (Hjelle et al., 1994). There are a number ofcomes rapidly bound to upregulated IL-2 receptors. IFNg
would activate macrophages to produce TNF (Nathan et variants that have been detected by genotypic analysis
of C7, and this might explain why we found differental., 1983). Administration of IL-2 in high doses can cause
capillary leaking (Rosenstein et al., 1986) and activate levels of recognition of the SNV epitope on a panel of
HLA-C7 matched allogenic target cells. The detection ofNK cells to release more IFNg (Ortaldo et al., 1984).
Recently it has been reported that some CD4/ CTL can HLA-B 35-restricted CD8/ CTL epitope and the CD4/
CTL epitope suggests a heterogenous human CTL re-lyse autologous CD8/ CTL which may downregulate the
CD8/ CTL response (Piazza et al., 1997). Production of sponse to SNV-N protein.
In conclusion, CD8/ and CD4/ CTL epitopes on SNVthese cytokines could cause the capillary leak syndrome
in the lungs of patients with HPS. nucleocapsid protein have been identified using CD8/ and
CD4/ clones that were isolated from the peripheral bloodWhy do some individuals develop fulminant HPS and
others have less severe illness? The level of immune of patients with acute HPS. Further studies are needed to
define the role of SNV specific T cells in the HPS.activation may reflect the virus antigenic load, affected
by dose of inhaled virus and perhaps a stronger immune
response at higher doses. The HLA alleles of infected ACKNOWLEDGMENTS
individuals are likely to affect the magnitude of T cell We thank Jim Montoya for technical assistance and Kim Wojnowski
activation, with some haplotypes representing higher re- for typing the manuscript. This work was supported in part by the
Centers for Infectious Diseases Grant U50 CCU111372 and the Na-sponders than do other haplotypes. Recently, Mustonen
tional Institutes of Health Grant AI 07272.et al. reported an increased frequency of a more severe
course of nephropathia epidemica caused by Puumala
REFERENCEShantavirus in patients with HLA B8 (Mustonen et al., 1996).
The importance of the unique and cross-reactive virus Boyum, A. (1968). Isolation of mononuclear cells and granulocytes from
human blood. Scand. J. Clin. Lab. Invest. 21 (Suppl. 97), 77–89.epitopes on SNV-N which stimulated CD8/ and CD4/
Burke, D. S., Nisalak, A., Johnson, D., and Scott, R. M. (1988). A prospec-CTL needs to be further studied. These epitopes might
tive study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg.represent several or many sequences of SNV proteins
38, 172–180.
that could be presented by these patients’ HLA alleles. CDC (1993). Hantavirus pulmonary syndrome—United States. MMWR
We recently established another T cell line from another 43, 45–48.
Chizhikov, V. E., Spiropoulou, C. F., Morzunov, S. P., Monroe, M. C., Pe-cryopreserved vial of PBMC from the first patient with
ters, C. J., and Nichol, S. T. (1995). Complete genetic characterizationthe HLA C7 restricted CD8/ CTL. After short-term culture,
and isolation of Sin Nombre virus. J. Virol. 69, 8132–8136.the new T cell line kills autologous B-LCL pulsed with
Duchin, J. S., Koster, F. T., Peters, C. J., Simpson, G. L., Tempest, B.,
the peptide 39H to a high level of lysis (67% at E:T 10:1). Zaki, S. R., Ksiazek, T. G., Rollin, P. E., Nichol, S., Umland, E. T., Moole-
These results suggest that the CD8/ CTL response to naar, R. L., Reef, S. E., Nolte, K. B., Gallaher, M. M., Butler, J. C., Brei-
man, R. F., and Hantavirus study group (1994). Hantavirus pulmonarythis SNV-N epitope was dominant in this patient but epi-
syndrome: A clinical description of 17 patients with a newly recog-topes on other proteins need to be defined. In the second
nized disease. N. Engl. J. Med. 330, 949–955.patient we identified another CD8/ T cell epitope re-
Earl, P. L., and Moss, B. (1991). Expression of proteins in mammalian
stricted by HLA B35 and a CD4/ T cell epitope. Analyses cells using vaccinia viral vectors. In ‘‘Current Protocols in Molecular
will need to be performed on T cells in the PBMC and Biology’’ (F. M. Ausubel, Ed.), Vol. 2, pp. 16.15.1–16.19.9. Wiley, New
York.lungs of other patients infected with SNV. Patients have
Earl, P. L., Koenig, S., and Moss, B. (1991). Biological and immunologicalhad fulminant HPS when infected with other SNV-like
properties of human immunodeficiency virus type 1 envelope glyco-viruses that have mutations in these epitopes which re-
protein: Analysis of proteins with truncations and deletions ex-
sults in nonrecognition by these CD8/ and CD4/ CTL pressed by recombinant vaccinia viruses. J. Virol. 65, 31–41.
clone. We have preliminary data (M. Mori et al.) that the Engelhard, V. H. (1994). Structure of peptides associated with class I
and class II MHC molecules. Annu. Rev. Immunol. 12, 181–207.lung tissues of four other patients who died with HPS
Feldmann, H., Sanchez, A., Morzunov, S., Spiropoulou, C. F., Rollin, P. E.,have infiltrating T cells in their alveolar tissues, confirm-
Ksiazek, T. G., Peters, C. J., and Nichol, S. T. (1993). Utilization ofing the observation by Zaki et al. (1995). Presumably all
autopsy RNA for the synthesis of the nucleocapsid antigen of a newly
patients with HPS have brisk T responses to epitopes recognized virus associated with hantavirus pulmonary syndrome.
on SNV proteins and the epitopes recognized by T cells Virus Res. 30, 351–367.
Halstead, S. B. (1988). Pathogenesis of dengue. Challenge to molecularwould vary depending on the HLA alleles of the patients.
biology. Science 239, 476–481.One of these CD8/ CTL epitopes is another example
Henderson, W. W., Monroe, M. E., St. Jeor, S. C., Thayer, W. P., Rowe,of a viral epitope restricted by a HLA C allele. Our group
J. E., Peters, C. J., and Nichol, S. T. (1995). Naturally occurring Sin
first noted that HLA-C alleles could restrict CD8/ CTL Nombre virus genetic reassortants. Virology 213, 602–610.
during a human infection when we defined an HLA-Cw3 Hjelle, B., Chavez-Giles, F., Torrez-Martinez, N., Yates, T., Sarisky, J.,
Webb, J., and Ascher, M. (1994). Genetic identification of a novelrestricted allele on HIV-1 p24 (Littaua et al., 1991). Subse-
AID VY 8827 / 6a53$$$644 11-07-97 16:21:27 vira AP: VY
390 ENNIS ET AL.
hantavirus of the harvest mouse Reithrodontomys megalotis. J. Virol. antigen for these immunoregulatory effects. J. Immunol. 133, 779–
783.68, 6751–6754.
Hjelle, B., Jenison, S., Torrez-Martinez, N., Yamanda, T., Nolte, K., Zum- Parrington, M. A., and Kang, C. Y. (1990). Nucleotide sequence analysis
of the S. genomic segment of Prospect Hill virus: Comparison withwalt, R., MacInnes, K., and Myers, G. (1994). A novel hantavirus
associated with an outbreak of fatal respiratory disease in the south- the prototype hantavirus. Virology 175, 167–175.
Pearson, A., Richardson, C., and Yuen, L. (1991). The 5* noncodingwestern United States: Evolutionary relationship to known hantavi-
ruses. J. Virol. 68, 592–596. region sequence of the choristoneura biennis entomopoxvirus spher-
oidin gene functions as an efficient late promoter in the mammalianHjelle, B., Krolikowski, I., Torrez-Martinez, N., Chavey-Giles, F., Vannery-
aud, C., and Laposata, E. (1995). Phylogenetically distinct hantavirus vaccinia expression system. Virology 180, 561–566.
Piazza, C., Montani, M. S. G., Moretti, S., Canclori, E., and Piccolella, E.implicated in a case of hantavirus pulmonary syndrome in the north-
eastern United States. J. Med. Virol. 46, 21–27. (1997). CD4/ T cells kill CD8/ T cells via Fas/Fas ligand-mediated
apoptosis. J. Immunol. 158, 1503–1506.Huang, C., Jin, B., Wang, M., Li, E., and Sun, C. (1993). Hemorrhagic
fever with renal syndrome: Relationship between pathogenesis and Powell, G. M. (1954). Hemorrhagic fever. A study of 300 cases. Medicine
33, 97–153.cellular immunity. J. Infect. Dis. 169, 868–870.
Johnson, R. P., Trocka, A., Buchanon, J. M., and Walker, B. D. (1993). Rosenstein, M., Ettinghausen, S. E., and Rosenberg, S. A. (1986). Extrav-
asation of intravascular fluid by the systemic administration of recom-Recognition of a highly conserved region of human immunodefi-
ciency virus type 1 gp 120 by an HLA-Cw4-restricted cytotoxic T- binant interleukin 2. J. Immunol. 137, 1735–1742.
Schmaljohn, A. L., Li, D., Negley, D. L., Bressler, D. S., Turell, M. J.,lymphocyte clones. J. Virol. 67, 438–445.
Koster, F. T., and Jenison, S. (in press). The Hantaviruses. In ‘‘Infectious Korch, G. W., Ascher, M. S., and Schmaljohn, C. S. (1995). Isolation
and initial characterization of a newfound hantavirus from California.Diseases’’ (S. L. Gorbach, J. G. Bartlett, and N. R. Blacklow, Eds.), 2nd
ed., 2140 –2147. Sanders, Orlando. Virology 206, 963–972.
Schmaljohn, C. S., Jennings, G. B., Hoyand, J., and Dalrymple, J. M.Kouri, G., Guzman, M. G., and Bravo, J. (1986). Hemarrhagic dengue in
Cuba: History of an epidemic. Pan Am. Health Org. Bull. 20, 24–30. (1986). Coding strategy of the S genome segment of Hantaan virus.
Virology 155, 633–643.Ksiazek, T. G., Peters, C. J., Rollins, P. E., Zaki, S. R., Nichol, S., Spiropou-
lou, C. F., Motzunov, S., Feldman, H., Sanchez, A., Khan, A., Mahy, Scott, R. M., Nimmannitya, S., Bancroft, W. H., and Mansuwan, P. (1976).
Shock syndrome in primary dengue infections. Am. J. Trop. Hyg. 26,B., Wacksmith, K., and Butler, J. (1995). Identification of a new North
American hantavirus that causes acute pulmonary insufficiency. Am. 337–343.
Spiropoulou, C. F., Morzunov, S., Feldmann, H., Sanchez, A., Peters,J. Trop. Med. Hyg. 52, 1017– 1023.
Kurane, I., Innis, B., Nimmannitya, S., Nisalak, A., Meager, A., Janus, J., C. J., and Nichol, S. T. (1994). Genome structure and variability of a
virus causing hantavirus pulmonary syndrome. Virology 200, 715–and Ennis, F. A. (1991). Activation of T lymphocytes in dengue virus
infections. High levels of soluble interleukin 2 receptor, soluable 723.
Stohwasser, R., Giebel, L. B., Zoeller, L., Bautz, E. K. F., and Darai, G.CD8, interleukin 2 and interferon-g in sera of children with dengue.
J. Clin. Invest. 88, 1473–1480. (1990). Molecular characterization of the RNA S segment of nepho-
pathia epidemia virus strain Haellnaes B. Virology 174, 79–86.Littaua, R. A., Oldstone, M. B. A., Takeda, A., Debouck, C., Wong, J. T.,
Tuazon, C. U., Moss, B., Kievits, F., and Ennis, F. A. (1991). An HLA- Takahashi, K., Dai, L-C., Fuerst, T. R., Biddison, W. E., Earl, P. L., Moss,
B., and Ennis, F. A. (1991). Specific lysis of human immunodeficiencyC restricted CD8/ cytotoxic T-lymphocyte clone recognizes a highly
conserved epitope on human immunodeficiency virus type 1 gag. J. virus type-1 infected cells by a HLA-A 3.1 restricted CD8/ cytotoxic
T-lymphocyte clone that recognize a conserved peptide sequenceVirol. 65, 4051–4056.
Lukes, R. (1954). The pathology of thirty-nine fatal cases of epidemic within the gp 4 or subunit of the envelope protein. Proc. Natl. Acad.
Sci. USA 88, 10277–102881.hemorrhagic fever. Am. J. Med. 16, 639–650.
Mustonen, J., Partanen, J., Kanerva, M., Pietila, K., Vapalahti, O., Pas- Walker, B. D., Flexner, C., Birch-Linberger, K., Fisher, L., Paradis, T. J.,
Aldovine, A., Young, R., Moss, B., and Schooley, R. T. (1989). Long-ternack, A., and Vaheri, A. (1996). Genetic susceptibility to severe
course of nephropathia epidemica caused by Puumala hantavirus. term culture and fine specificity of human cytotoxic T-lymphocyte
clones reactive with human immunodeficiency virus type 1. Proc.Kidney Int. 49, 217–221.
Nathan, C. F., Murray, M. W., Wiebe, M. E., and Rubin, B. Y. (1983). Natl. Acad. Sci. USA 86, 9514–9518.
Williams, R. C., Troup, G. M., Nelson, J. L., Kostya, D. D., McAuby, D. E.,Identification of interferon-g as the lymphokine that activates human
macrophage oxidative metabolism and antimicrobial activity. J. Exp. Petutt, D. J., Knowler, W. C., Temphi, D. W., Mickelson, E. M., Hansen,
J. A., and Hoy, W. (1992). ‘‘Reports of the North American IndianMed. 158, 670–689.
Nerukar, V. R., Song, J. W., Song, K. J., Nagle, J. W., Hjelle, B., Jennison, Authropology Sections in HLA 1991’’ (K. Tsuji, M. Aizawa, and T.
Sasazuki, Eds.), pp. 683–685. Oxford Univ. Press, Oxford.S., and Yanagihara, R. (1994). Genetic evidence for a hantavirus
enzootic in deer mice (Peromyscus maniculatus) captured a decade Xiao, S. Y., Spik, K. W., Li, D., and Schmaljohn, C. S. (1993). Nucleotide
and deduced amino acid sequences of the M and S genome seg-before the recognition of hantavirus pulmonary syndrome. Virology
204, 563–568. ments of true Puumala virus isolates from Russia. Virus Res. 30, 97–
103.Nichol, S. T., Spiropoulou, C. F., and Morzunov, S., et al. (1993). Genetic
identification of a hantavirus associated with an outbreak of acute Zaki, S. R., Greer, R. W., Coffield, L. S., Goldsmith, C. S., Nolte, K. B.,
Coucar, K., Feddersen, R. M., Zumwalt, R. E., Miller, G. C., Khan, A. S.,respiratory illness. Science 262, 914–917.
Ortaldo, J. R., Mam, A. T., Gerard, J. P., Henderson, L. E., and Farrar, W. Rollin, P. E., Ksiazek, T. G., Nichol, S. T., Mahy, B. W. J., and Peters,
C. J. (1995). Hantavirus Pulmonary Syndrome: Pathogenesis of an(1984). Effects of natural and recombinant IL2 on regulation of IFNg
production and natural killer activity: Lack of involvement of the Tac emerging infectious Disease. Am. J. Pathol. 146, 552–579.
AID VY 8827 / 6a53$$$645 11-07-97 16:21:27 vira AP: VY
